FIT Biotech Oy
Company release December 15, 2016 at 19:00 pm EET
Directed share issue of FIT Biotech Oy
The Board of Directors of FIT Biotech Oy ("Company") has resolved on December 14, 2016, by virtue of the authorization of General Meeting on April 8, 2016, to issue 213,763 new K-shares as a directed share issue.
FIT Biotech Oy carries out the directed share issue to Translink Corporate Finance Oy ("Translink") as a reward for Translink's provided services as per the advisor agreement that was in force between Company and Translink. There are weighty financial reasons for the share issue since the purpose of the issue is to strengthen the Company's capital structure and cash funds. New shares represent 0.52 % of Company's outstanding shares before the issue of the new shares. Translink has earlier acted as Company's Certified Advisor.
The shares are issued with the following terms and conditions:
1.The Shares and Subscription Rights
The Company issues 213,763 new K-shares. The shares are offered to Translink Corporate Finance Oy ("Translink") deviating from the pre-emptive rights of shareholders referred to in Chapter 9 Section 3 of Finnish Companies Act.
There are weighty financial reasons for the share issue since the purpose of the issue is to strengthen the Company's capital structure and cash funds.
2. Subscription Price
The subscription price totals EUR 41,450 being ca EUR 0.19391 per share. The subscription price for the shares is based on share price in FIRST NORTH trading before the share issue, which shall be considered the fair value of the shares.
The subscription price is paid fully with receivable of EUR 41,450 of Translink from the Company.
The Subscription Price shall be recorded in its entirety into the equity capital.
3. Subscription Period and Time of Payment
The Shares are regarded as subscribed after the resolution of the Board of Directors. The shares are considered to be paid when subscribed.
4. Right to Dividend and Other Rights
The new shares will entitle their holders to shareholder rights, including the
right to receive full dividends declared by the Company, if any, after the shares have been registered with the Trade Register.
5. Book Entry System and Trading of Shares
The Shares will be issued in book-entry form in the Finnish book-entry
securities system operated by Euroclear Finland Ltd after their registration with the Trade Register.
The Company shall apply the listing of the new shares together with the other shares in the Company on the NASDAQ FIRST NORTH List.
6. Other Issues
The Board of Directors of the Company will decide on other matters related to
the share issue and practical arrangements resulting therefrom.
FIT BIOTECH OY
Board of Directors
For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media